Distribution of Biosimilar Pharmaceuticals Through Third Parties is Not Enough to Avoid Personal Jurisdiction
By EsqSocial Corporation 09/04/25
In Regeneron Pharms., Inc. v. Mylan Pharms. Inc., the Federal Circuit recently held that biosimilar pharmaceutical companies that filed abbreviated Biologics License Applications (aBLAs) and planned to make a single sale to a third-party marketer were subject to personal jurisdiction in West Virginia, even though the third-party marketers would distribute the product....
By: DLA Piper